Mibefradil

This classification denotes a calcium channel blocker with the molecular formula C29H38FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27B90X776A, chemically known as acetic acid, methoxy-, 2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride, (1s-cis)- but generally known as mibefradil, which bears US NIH Compound Identifier 60662. European Medicines Agency schedules Mibefradil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08940MIG. The term MIBEFRADIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules mibefradil in its Anatomical Therapeutic Chemical (ATC) Classification. MIBEFRADIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mibefradil under HS 29339990 and SITC 51577. As of Q4 2014, MIBEFRADIL remains the US FDA Preferred Term for this commodity. Mibefradil bears US NLM identifiers UMLS ID C0286185 and NCI Concept Code C87686. SMILES: Cl.Cl.Fc1cc2c(C(C(OC(=O)COC)(CC2)CCN(CCCc2[nH]c3c(n2)cccc3)C)C(C)C)cc1.